Navigation Links
Research points to potential window for treating CMV and preventing mother-to-child transmission
Date:10/30/2013

ection, and nearly 20 percent exhibit permanent neurologic effects such as hearing loss or developmental delay.

To better understand how CMV evolves in fetuses and newborns during symptomatic congenital infection, researchers at UMMS and the University of Minnesota Medical School collected samples from the plasma and urine of five congenitally infected infants during the first year after birth. Using next generation DNA sequencing, Kowalik and colleagues studied the diversity and changes in viral DNA sequences over time and between organs. Though the DNA sequences from viruses taken from the same type of sample (e.g. plasma) were similar to each other, the study's authors found dramatic differences between the sequences collected from viruses in the plasma and urine of the same infant. Surprisingly, the plasma and urine sequences from the same infant were as different as sequences from two unrelated infants.

These results suggest that CMV is able to evolve very quickly as the differences between the plasma and urine sequences likely occurred in the short period between the initial, in utero infection, and the first year after birth. However, the mechanism driving this phenomenon remained unclear.

To answer this question, researchers used mathematical modeling and statistical inference to uncover evidence that population bottlenecks and expansions may play a significant role in the virus' evolution after infection. Characterized by a substantial reduction in viral copies followed by a quick rebound, population bottlenecks and expansions can lead to dramatic changes in DNA sequences that result in two related populations quickly becoming dissimilar. In the case of CMV infection, this phenomenon appeared to coincide with the virus moving from the mother to the fetus and later migrating from the plasma to the kidneys.

The model also suggests that the timing of initial fetal infection in the patients was at 13 to 18 weeks gestati
'/>"/>

Contact: Jim Fessenden
james.fessenden@umassmed.edu
508-856-2000
University of Massachusetts Medical School
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Experts from NYU Langone present new research at American College of Rheumatology 2013 Annual Meeting
2. NSF, US Antarctic Program partners, working to restore Antarctic research season to the maximum extent possible
3. Expanding research communities and collaborations
4. NREL researcher honored with Hispanic STEM award
5. Researchers quantify toxic ocean conditions during major extinction 93.9 million years ago
6. OU research team finds a common bioindicator resistant to insecticides
7. Dr. Avrum Spira receives award for advancing research on tobacco smokes effect on lungs
8. Researchers discover how cancer invisibility cloak works
9. Oregon researchers say supplement cuts muscle loss in knee replacements
10. BUSM researchers identify molecule that could aid lung cancer detection, treatment
11. USC researcher reveals how to better master stem cells fate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , August 26, 2015 ... Four, and Five Factor), Application (Travel & Immigration, Government, ... - Global Forecast to 2020", published by MarketsandMarkets, Multi-Factor ... by 2020, growing at a CAGR of 17.7% between ... and 82 F igures spread through 169 ...
(Date:8/20/2015)... PLEASANTON, Calif. , Aug. 20, 2015 /PRNewswire/ ... focused on consumers that are active and healthy. ... used in the hospital environment to help improve ... released a video from the Wearable Technologies ... MD discussed new applications for wearables in healthcare.    ...
(Date:8/18/2015)... 2015  Navitas today announced that it ... Submission Content Management webinar scheduled on August ... to the Implementation of Regulatory Submission Standards ... industry, vendors, health authorities, consultants and the ... a standard method of implementing electronic submission ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... in the February 15th issue of Genes & Development ... in sperm while they reside in the female reproductive ... of successful fertilization. , It had been believed for ... Gur and Haim Breitbart (Bar-Ilan University, Israel) now show ...
... A version of a gene previously linked to ... regulate impulses, emotional memory and thinking in humans, ... National Institute of Mental Health (NIMH) have found. ... ?especially males ?tended to have relatively smaller emotion-related ...
... lactic acid is poison, a waste product that builds ... reduced performance and pain. , Some 30 years of ... a different story: Lactic acid can be your friend. ... physiologist George Brooks, UC Berkeley professor of integrative biology, ...
Cached Biology News:Aggression-related gene weakens brain's impulse control circuits 2Aggression-related gene weakens brain's impulse control circuits 3Lactic acid not athlete's poison, but an energy source - if you know how to use it 2Lactic acid not athlete's poison, but an energy source - if you know how to use it 3Lactic acid not athlete's poison, but an energy source - if you know how to use it 4
(Date:9/2/2015)... 2015 Research and Markets ... PharmaBiotech,s new report "Gene Therapy - Technologies, Markets ... markets for gene therapy are difficult to estimate as ... it is marketed in China ... years 2014-2024. The estimates are based on epidemiology of ...
(Date:9/2/2015)... ... September 02, 2015 , ... Drug companies increasingly ... BCC Research reveals in its new report that the U.S. will generate ... category and generates the most market demand. , BCC Research examines plant-derived ...
(Date:9/2/2015)... Colo. , Sept. 2, 2015 Aytu ... on developing treatments for urological and related conditions, announced ... its planned private placement convertible note financing, raising a ... prior tranches totaling $3.175 million. ... "Proceeds from this private placement are intended to be ...
(Date:9/2/2015)... Israel , September 2, 2015 ... intent of the National Institute of Allergy and Infectious Diseases ... within the Department of Health and Human Services (HHS), to ... the United States in the 2015-16 ... flu vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, which ...
Breaking Biology Technology:Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3
... BioSpace, the world,s leading,online bioscience job board ... biotechnology and pharmaceutical job candidates at its Biotech,Bay ... 4, 2008., The BioSpace Career Fair drew ... and diagnostics career candidates from,around the Northern California ...
... Data on ARIUS, novel CD9 therapeutic antibody to be presented ... Special Conference on Cancer ... Research Inc., (TSX:,ARI), a biotechnology company discovering and developing the ... the,preclinical activity of its anti-CD9 cancer stem cell antibody will ...
... Latin American Country to Approve Treatment, ... Shire plc (LSE: SHP)(NASDAQ: SHPGY )(TSX: ... ELAPRASE(R),(idursulfase), a human enzyme replacement therapy for ... for commercial sale by the Mexican,Federal Commission ...
Cached Biology Technology:BioSpace Career Fair in San Francisco Welcomes Over 1,000 Bioscience Professionals 2ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells 2ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells 3ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells 4Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome 2Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome 3Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome 4
... using PULSin may be superior to transfection ... traditional transfection, with PULSin you can study ... time course of proteins in cells. Likewise, ... information than traditional RNA interference experiments. ...
... innovative reagent for highly efficient transfer of ... cells. Unlike DNA transfection, with PULSin Protein ... timing of exogenous proteins in cells can ... be studied. Real time function blocking ...
Reacti-Bind DNA Coating Solution...
... Solutions has now entered the next frontier ... partnering up with Cellomics, Inc. The drug ... of Beckman Coulter‘s automated solutions systems and ... information at the sub-cellular level. The integration ...
Biology Products: